1. Acute hepatitis C: analysis of a 126-case prospective, multicenter cohort.
- Author
-
Morin T, Pariente A, Lahmek P, Rabaud C, Silvain C, and Cadranel JF
- Subjects
- Acute Disease, Adolescent, Adult, Aged, Antiviral Agents therapeutic use, Belgium epidemiology, Drug Therapy, Combination, Female, France epidemiology, HIV Infections epidemiology, Hepacivirus genetics, Humans, Interferon Type I therapeutic use, Luxembourg epidemiology, Male, Middle Aged, Prospective Studies, RNA, Viral blood, Recombinant Proteins, Registries, Remission, Spontaneous, Ribavirin therapeutic use, Risk Factors, Time Factors, Treatment Outcome, Viral Load, Young Adult, Hepatitis C diagnosis, Hepatitis C drug therapy, Hepatitis C epidemiology, Hepatitis C transmission
- Abstract
Objectives: To analyze the data (epidemiology, mode of transmission, course, and outcome) of a large series of patients with acute hepatitis C (AHC) in France., Methods: Prospective multicenter register, observational study., Results: A cohort of 126 patients with AHC was prospectively enrolled between 1999 and 2007. Fifteen (12%) were HIV coinfected. Suspected modes of hepatitis C virus transmission were drug use (38%), sexual contact (21%), nosocomial transmission (18%), and occupational exposure (12%). For 40% of the patients, AHC was revealed by jaundice. Spontaneous viral clearance occurred in 40% of the 72 patients observed for 3 months without treatment. Only jaundice and nosocomial/occupational transmission were predictive of spontaneous viral clearance. Ninety patients were treated with standard or pegylated interferon-alpha alone (58%) or in combination with ribavirin (42%), for 24 weeks or less in 90%. In intention-to-treat, a sustained viral response was obtained in 58 of 78 (74%) hepatitis C virus monoinfected patients [19 of 22 (86%) with 24 weeks of pegylated interferon-alpha alone], but only six of 12 (50%) of HIV coinfected patients., Conclusion: AHC remains rare, and drug and sexual transmission are predominant. A 3-month follow-up after diagnosis avoids treatment for four out of 10 patients. Antiviral treatment is highly effective, 24 weeks of pegylated interferon-alpha alone being a good option.
- Published
- 2010
- Full Text
- View/download PDF